Literature DB >> 22594502

Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

Thomas J Urban, David B Goldstein, Paul B Watkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22594502      PMCID： PMC3641893          DOI： 10.2217/pgs.12.45

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  16 in total

Review 1.  EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.

Authors:  Mariam Molokhia; Paul McKeigue
Journal:  Pharmacogenomics       Date:  2006-06       Impact factor: 2.533

2.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.

Authors:  A Kindmark; A Jawaid; C G Harbron; B J Barratt; O F Bengtsson; T B Andersson; S Carlsson; K E Cederbrant; N J Gibson; M Armstrong; M E Lagerström-Fermér; A Dellsén; E M Brown; M Thornton; C Dukes; S C Jenkins; M A Firth; G O Harrod; T H Pinel; S M E Billing-Clason; L R Cardon; R E March
Journal:  Pharmacogenomics J       Date:  2007-05-15       Impact factor: 3.550

3.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

4.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

Authors:  Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

5.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Authors:  M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly
Journal:  Gastroenterology       Date:  2011-04-12       Impact factor: 22.682

Review 6.  Genetic association studies in drug-induced liver injury.

Authors:  Ann K Daly; Christopher P Day
Journal:  Drug Metab Rev       Date:  2011-09-14       Impact factor: 4.518

7.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

8.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Authors:  Ann K Daly; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; Matthew R Nelson; Julia Graham; B Kevin Park; John F Dillon; William Bernal; Heather J Cordell; Munir Pirmohamed; Guruprasad P Aithal; Christopher P Day
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

Review 10.  Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.

Authors:  Michael V Holmes; Tina Shah; Christine Vickery; Liam Smeeth; Aroon D Hingorani; Juan P Casas
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240
View more
  10 in total

1.  NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.

Authors:  Rika Yuliwulandari; Retno Wilujeng Susilowati; Britanto Dani Wicaksono; Kencono Viyati; Kinasih Prayuni; Intan Razari; Erna Kristin; Eva Sri Diana; Suci Setiawati; Aziza Ariyani; Surakameth Mahasirimongkol; Hideki Yanai; Taisei Mushiroda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  The Opportunities of Metabolomics in Drug Safety Evaluation.

Authors:  Pengcheng Wang; Amina I Shehu; Xiaochao Ma
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

Review 3.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

4.  Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers.

Authors:  Maria João Cavaco; Celeste Alcobia; Bárbara Oliveiros; Luís Alcides Mesquita; Aurora Carvalho; Fernando Matos; José Miguel Carvalho; Miguel Villar; Raquel Duarte; João Mendes; Carolina Ribeiro; Carlos Robalo Cordeiro; Fernando Regateiro; Henriqueta Coimbra Silva
Journal:  J Pers Med       Date:  2022-05-13

5.  Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.

Authors:  Thomas Jacob Urban; Paola Nicoletti; Naga Chalasani; José Serrano; Andrew Stolz; Ann K Daly; Guruprasad P Aithal; John Dillon; Victor Navarro; Joseph Odin; Huiman Barnhart; David Ostrov; Nanye Long; Elizabeth Trilby Cirulli; Paul Brent Watkins; Robert John Fontana
Journal:  J Hepatol       Date:  2017-03-18       Impact factor: 25.083

6.  Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.

Authors:  K Yang; J L Woodhead; P B Watkins; B A Howell; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2014-07-28       Impact factor: 6.875

Review 7.  Signal transducer and activator of transcription 4 in liver diseases.

Authors:  Yan Wang; Aijuan Qu; Hua Wang
Journal:  Int J Biol Sci       Date:  2015-02-27       Impact factor: 6.580

8.  Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity.

Authors:  Yukti Choudhury; Yi Chin Toh; Jiangwa Xing; Yinghua Qu; Jonathan Poh; Huan Li; Hui Shan Tan; Ravindran Kanesvaran; Hanry Yu; Min-Han Tan
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

9.  Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity.

Authors:  Christina Battista; Kyunghee Yang; Simone H Stahl; Jerome T Mettetal; Paul B Watkins; Scott Q Siler; Brett A Howell
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

10.  A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.

Authors:  Elizabeth T Cirulli; Paola Nicoletti; Karen Abramson; Raul J Andrade; Einar S Bjornsson; Naga Chalasani; Robert J Fontana; Pär Hallberg; Yi Ju Li; M Isabel Lucena; Nanye Long; Mariam Molokhia; Matthew R Nelson; Joseph A Odin; Munir Pirmohamed; Thorunn Rafnar; Jose Serrano; Kári Stefánsson; Andrew Stolz; Ann K Daly; Guruprasad P Aithal; Paul B Watkins
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.